BACKGROUND INFORMATION ON THE PROCEDURE 
1.1  Submission of the dossier 
The  applicant  Schwarz  Pharma  Ltd.  submitted  on  29  September  2004  an  application  for  Marketing 
Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Neupro,  through  the  centralised 
procedure. 
The legal basis for this application refers to:  
Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application, (i.e. 
complete dossier with administrative, quality, non-clinical and clinical data). 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
The Rapporteur and Co-Rapporteur appointed by the CHMP: 
Rapporteur: 
C. Sampaio 
Co-Rapporteur 
B. van Zwieten-Boot 
1.2  Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 29 September 2004.  
The procedure started on 18 October 2004. 
The Rapporteur's first Assessment Report was circulated to all CHMP members on 10 January 
2005 and on 18 January 2005 . The Co-Rapporteur's first Assessment Report was circulated to 
all CHMP members on 7 January 2005 and on 10 January 2005).  
During the meeting in February 2005, the CHMP agreed on the consolidated List of Questions 
to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on  
18 February 2005. 
The applicant submitted the responses to the CHMP consolidated List of Questions on 2 August 
2005. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 21 September 2005 . 
During the CHMP meeting in October 2005, the CHMP agreed on a List of Outstanding Issues 
to be addressed in writing and in an oral explanation by the applicant. 
The applicant submitted the responses to the CHMP List of Outstanding Issues on 25 October 
2005. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of outstanding issues to all CHMP members on 9  November 2005. 
During  the  CHMP  meeting  in  November  2005,  outstanding  issues  were  addressed  by  the 
applicant  during  an  oral  explanation  before  the  CHMP  and  the  CHMP  agreed  on  a  list  of 
outstanding issues to be addressed in writing by the applicant. 
The applicant submitted the responses to the CHMP List of Outstanding Issues on 24 November 
2005. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of outstanding issues to all CHMP members on 7 December 2005. 
During the meeting in December 2005, the CHMP, in the light of the overall data submitted and 
the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to Neupro on 15 December 2005. The applicant provided the letter of 
undertaking on the follow-up measures to be fulfilled post-authorisation on 9 December 2005. 
1/1 
 
 
 
 
 
 
 
 
 
 
  
 
 
